Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03161522 2025-10-23

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2 Recruiting

100 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT05051475 2025-10-03

RATE

Phase NA Completed

62 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Phase 1/2 Active not recruiting

64 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

3 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT06687876 2025-07-10

MEMENTO

Phase 2 Recruiting

14 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT02366819 2025-06-13

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Phase 4 Recruiting

36 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06933966 2025-04-18

ATTENUATION

Phase 2 Not yet recruiting

120 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT03429816 2025-03-27

OPPOSITE

Phase NA Completed

120 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT04114136 2025-02-10

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

72 enrolled

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT03366012 2024-11-08

REACT

Phase NA Terminated

51 enrolled 4 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT05476796 2024-10-24

LOGICAN

Phase 2 Recruiting

118 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT05713838 2024-09-19

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Phase 2 Recruiting

32 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT01404156 2024-08-28

POWERRANGER

Phase 2/3 Completed

29 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT05177133 2024-08-02

AuspiCiOus

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Microsatellite Instability

NCT03641547 2024-07-18

CHARIOT

Phase 1 Completed

36 enrolled 24 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT05530343 2024-06-12

SWAT-BE

Phase NA Recruiting

2,298 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04159974 2024-05-09

RICE

Phase 2 Unknown

56 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02509286 2024-05-08

ESOPEC

Phase 3 Active not recruiting

438 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03339843 2024-03-15